Fw: [ RadSafe ] Comments on thyroid cancer paper by E. Cardis et al.
mark.hogue at srs.gov
mark.hogue at srs.gov
Mon Dec 12 08:30:23 CST 2005
Bobby,
Thank you for the interesting post. It seems appropriate to me that you
post this relevant question. I don't have an immediate response to your
technical questions, but would like to offset the discouraging responses
posted so far:
1. One post suggested you should write to the journal rather than Radsafe.
Obviously, you know about journal correspondence and are just determining
if there is a proper case. Some people on Radsafe feel they have to
respond to every post though and will state the obvious if they know
nothing else.
2. The other post stated that there is very little knowledge of
epidemiology on Radsafe. I hope this is not true, but it is bizarre to
discourage a technical post amid the irrelevant nuisance posts on the
basis that this one is too hard to think about.
Good luck in your endeavor.
Mark G. Hogue, CHP
mark.hogue at srs.gov
"But we surely overrate the usefulness of what we like to call
"stimulation" and underrate the need for time, peace of mind, mature
reflection." - Susan Haack
"DISCLAIMER: The opinions expressed are mine and do not necessarily
represent Westinghouse Savannah River Co. or the United States Department
of Energy."
"Scott, Bobby" <BScott at lrri.org>
Sent by: radsafe-bounces at radlab.nl
12/11/2005 04:42 PM
To
<radsafe at radlab.nl>
cc
Subject
[ RadSafe ] Comments on thyroid cancer paper by E. Cardis et al.
Comments on Thyroid Cancer Paper by E. Cardis et al.
Paper: E. Cardis et al., Risk of Cancer After Exposure to I-131 in
Childhood
Journal: Journal of the National Cancer Institute Vol. 97, No. 10 pages
724-732, May 18, 2005.
The authors carried out a population-based, case-control study of
thyroid cancer in Belarus and the Russian Federation to evaluate the
risk of thyroid cancer after exposure to radioactive iodine (mainly
I-131) from the 1986 Chernobyl accident and to investigate environmental
and host factors that may modify the risk. The study involved 276 case
patients with thyroid cancer through 1998 and 1300 matched control
subjects, all younger than 15 years at the time of the Chernobyl
accident. Linear and linear-quadratic excess relative risk models were
fit to the data using conditional logistic regression. A strong
dose-response relationship was found between the calculated absorbed
radiation dose to the thyroid received in childhood and thyroid cancer
(P<0.001). A linear dose-response relationship was stated to have been
observed up to 1.5 - 2 Gy.
This e-mail questions the claim of a linear dose-response relationship
in light of the large errors associated with the derived odd ratios (OR)
and also questions the methods used for employing nonlinear
dose-response models. The data reported in Figure 1 of the paper that
were used to obtain odds ratio (an estimate of relative risk) are
provided below:
Dose interval (mGy), cases in the interval, controls in the interval:
Interval 0-15 mGy, cases=16, controls=138;
Interval 16-199 mGy, cases=76, controls=503;
Interval 200-399 mGy, cases=40, controls=200;
Interval 400-599 mGy, cases=31, controls=141;
Interval 600-799 mGy, cases=29; controls=92;
Interval 800-999 mGy, cases=26, controls=67;
Interval 1000-1249 mGy, case=14, controls=60;
Interval 1250-1499 mGy, cases=10, controls=22;
Interval 1500-1999 mGy, cases=10, controls=23;
Interval 2000-2999 mGy, cases=15, controls=25;
Interval 3000 mGy and larger, cases=9, controls=29;
OR was apparently evaluated relative to the interval 0-15 mGy. The crude
OR I get for the interval 16-199 mGy is: 1.303 (0.736, 2.307). The two
values within the parenthesis defines the 95% confidence interval. Note
that the result is not significant > 0 and based on the lower confidence
value is consistent with the possibility of either a threshold or a
hormetic response. Neither a threshold or hormetic model were considered
by the researchers. The indicated results related to the threshold and
hormetic models are especially important in that there was no actual
unexposed group. Not having an unexposed group and using a case-control
study design can greatly favor LNT over threshold and hormetic models.
Also, given that reconstructed doses (dose estimates) are likely at best
crude approximations, doses for some persons stated to be in the dose
interval 0-15 mGy could be much higher. The OR results I got appear to
differ from those reported by Cardis et al. However, how they got their
OR values was not explained in their paper. Possibly some unreported
adjustments were made.
The excess relative risk (RR) model used by Cardis et al. for OR (an
estimate of RR) had the structure:
OR = 1 + beta*D + gamma*D*D,
where D is the individual absorbed dose (usual definition in risk
assessment). Beta and gamma are fixed model parameters. In the
regression analysis, the above equation was apparently regressed against
average dose for each dose group. A fixed observed OR was assigned to
each dose interval. Please note that this implies that OR averaged over
each dose interval was assumed. For the linear model (gamma=0), there
is no problem because average OR (here indicated as Av{OR}) equals 1 +
beta*Av{D}, where Av{} again indicates average. However, for gamma not
equal to zero, Av{OR} is not only a function of Av{D}, but also a
function of Av{D*D}. Av{OR} is not a function of Av{D}*Av{D} as was
apparently used by Cardis et al. (systematic error in model
application?). Thus, conclusions obtained by the authors related to
application of the linear-quadratic function may not be valid.
For some analyses, instead of use of the excess RR model the authors
used and exponential form of OR, where
OR = exp(beta*D + gamma*D*D + ...).
However, they apparently did not realize that in using this exponential
model that
Av{OR} does not equal exp(beta*Av{D} + gamma*Av{D}*Av{D} + ...), but has
a more complicated structure that should have been used. Thus, results
reported by the authors based on this modeling may not be valid.
Radsafe Digest readers, comments on the above would be welcomed.
Sincerely,
Bobby R. Scott, Ph.D.
Senior Scientist
Lovelace Respiratory Research Institute
2425 Ridgecrest Drive SE
Albuquerque, NM 87108 USA
_______________________________________________
You are currently subscribed to the RadSafe mailing list
Before posting a message to RadSafe be sure to have read and understood
the RadSafe rules. These can be found at:
http://radlab.nl/radsafe/radsaferules.html
For information on how to subscribe or unsubscribe and other settings
visit: http://radlab.nl/radsafe/
More information about the RadSafe
mailing list